Oral GLP-1s are now a real comparison category, but the safest provider is still the one that slows checkout down.
The private UK market has moved beyond a simple Mounjaro versus Wegovy injection comparison. Wegovy tablets are live on major pharmacy pages, Foundayo has UK authorisation, and providers are starting to explain switching, dose ladders and access routes in more detail.
The main market story is practical rather than dramatic: patients can now compare tablets, injections, dose escalation, switching support and safety standards side by side. Boots lists Wegovy tablets and Foundayo in its treatment range, while Superdrug lists Wegovy pill stock from £99.
At the same time, medicine authenticity and clinical governance remain central. The MHRA continues to warn against illegal GLP-1 sellers, and recent reporting on counterfeit activity shows why regulated prescribing routes matter when demand rises.
In this round-up
Oral GLP-1s are no longer just future pipeline news
The MHRA authorised Wegovy tablets for weight management in June 2026 and authorised orforglipron, branded as Foundayo, in August 2026. That means provider pages can now discuss a broader oral GLP-1 market, even while availability, NHS access and private pricing still vary by service.
For patients, the comparison has changed. Tablets may remove injection anxiety, but they introduce their own dose schedules, administration rules, suitability checks and cost ladders. Superdrug's Wegovy pill page lists a daily tablet, stock status and pricing from £99, while Boots lists Wegovy tablets and Foundayo as separate weight-loss treatment options.
Compare oral options by confirmed availability, dose ladder, timing instructions, support, prescription checks and total monthly cost. Do not assume a tablet is automatically easier, cheaper or more suitable.
Counterfeit and illegal seller warnings are still part of the market story
The MHRA's patient guidance remains clear: prescription GLP-1 medicines should be supplied through appropriate clinical routes, and people should avoid unregulated websites, social media sellers and quick-fix claims. That warning matters more when demand rises and legitimate prices change.
Recent reporting also points to a growing industry and enforcement response around counterfeit weight-loss medicines. For comparison purposes, this makes provider trust signals more important: GPhC details, prescriber review, identity and BMI evidence checks, medicine authenticity and aftercare should be visible before payment.
A provider asking medical questions, requesting evidence and explaining suitability is doing necessary work. Treat instant access, no consultation, social-media-only selling or unusually cheap GLP-1 offers as warning signs.
Mounjaro price pressure makes switching support more important
Boots has published patient-facing guidance on Mounjaro price changes and discusses alternatives such as Wegovy where clinically suitable. Community Pharmacy England has also recorded the list-price change context, making it clear that the manufacturer price shift affects the wider UK supply chain, even though individual providers set their own private prices.
That does not mean patients should switch based on price alone. Tirzepatide, semaglutide and oral GLP-1 options have different active ingredients, dose schedules, response patterns and side-effect considerations. The provider's switching process is now a real comparison feature.
| Question | Why it matters | Good provider answer |
|---|---|---|
| Can I switch? | Your current dose, side effects and medical history affect suitability. | Clinician review before any change. |
| What will it cost later? | Starter prices can hide maintenance-dose cost. | Full dose ladder and subscription terms. |
| Is stock confirmed? | High demand can change availability quickly. | Clear stock and delivery information. |
| What if side effects happen? | GLP-1 treatment can need dose changes or pauses. | Accessible support and escalation advice. |
Provider pages are becoming more detailed, but not always easier to compare
- Oral Wegovy: check stock, dose availability, fasting rules and whether the full 25mg maintenance price is shown.
- Foundayo: separate UK authorisation from actual provider stock, NHS availability and long-term private pricing.
- Mounjaro: check whether the provider has updated all doses after price changes and whether support is included.
- Safety: look for regulated pharmacy details, prescriber review, evidence checks and clear adverse-event guidance.
Medical disclaimer
This article is for general information only and is not medical advice. Prescription medicines should only be used after assessment by a qualified healthcare professional.
Sources used
- MHRA: first GLP-1 tablet for weight loss approved in the UK
- MHRA: orforglipron authorised for weight management and type 2 diabetes
- MHRA: no summer shortcut for safe weight loss
- Superdrug Online Doctor: Wegovy Pill
- Boots Online Doctor: weight-loss treatment options
- Boots Online Doctor: Mounjaro price-change guidance
- Community Pharmacy England: Mounjaro reimbursement prices redetermined
- Financial Times: counterfeit weight-loss drug enforcement
